WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017181420) CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/181420    International Application No.:    PCT/CN2016/080025
Publication Date: 26.10.2017 International Filing Date: 22.04.2016
IPC:
C12N 15/869 (2006.01), C12N 15/33 (2006.01), A61K 48/00 (2006.01)
Applicants: IMMUNO VIR CO., LIMITED [CN/CN]; Building A16, Life Science Park 140 Jinye Ave., Dapeng New District Shenzhen, Guangdong 518119 (CN)
Inventors: ZHOU, Grace Guoying; (CN).
CHEN, Xiaoqing; (CN).
LIU, Xianjie; (CN)
Agent: WINGUAN PATENT AND TRADEMARK ATTORNEYS; 607 Sicheng Road 23, Tianhe District Guangzhou, Guangdong 510663 (CN)
Priority Data:
Title (EN) CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
(FR) CONSTRUCTION DE VECTEUR OBLIGATOIRE DE VIRUS HERPÈS SIMPLEX ONCOLYTIQUES (OHSV) ET CONSTRUCTIONS POUR LE TRAITEMENT DU CANCER
Abstract: front page image
(EN)An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.
(FR)L'invention concerne un vecteur obligatoire d'oHSV comprenant un génome d'ADN viral modifié. L'invention concerne également une construction d'oHSV-1 recombiné comprenant le vecteur obligatoire d'oHSV et une séquence d'acide nucléique hétérologue codant un agent immunostimulant et/ou immunothérapeutique. Des compositions comprenant la construction d'oHSV-1 recombiné peuvent être utilisées pour traiter les cancers.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)